In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
暂无分享,去创建一个
C. Adler | D. Jennings | T. Foroud | B. Mollenhauer | Peggy Taylor | T. Beach | D. Munoz | G. Serrano | M. Brumm | C. Coffey | C. White | K. Dave | J. Crary | V. Arnedo | C. Caspell-Garcia | L. Chahine | C. Kopil | Lindsey Riley | Sherri Mosovsky
[1] J. Volkmann,et al. Abnormal α‐synuclein deposits in skin nerves: intra‐ and inter‐laboratory reproducibility , 2019, European journal of neurology.
[2] L. Leclair-Visonneau,et al. Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification , 2019, Neurobiology of Disease.
[3] L. Romito,et al. Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy , 2019, Translational Neurodegeneration.
[4] F. Pontieri,et al. Alpha-synuclein in salivary gland as biomarker for Parkinson’s disease , 2019, Reviews in the neurosciences.
[5] Claudio Soto,et al. Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[6] K. Blennow,et al. Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study , 2018, Journal of neurochemistry.
[7] W. M. van der Flier,et al. α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies , 2018, Movement disorders : official journal of the Movement Disorder Society.
[8] Norbert Schuff,et al. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort , 2018, Annals of clinical and translational neurology.
[9] C. Adler,et al. Importance of low diagnostic Accuracy for early Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[10] C. Adler,et al. Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) , 2018, Journal of Parkinson's disease.
[11] C. Adler,et al. Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4) , 2018, Journal of neuropathology and experimental neurology.
[12] D. Brooks,et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study , 2018, The Lancet Neurology.
[13] Alberto J Espay,et al. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations , 2018, Movement disorders : official journal of the Movement Disorder Society.
[14] D. Galasko,et al. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC , 2018, Acta Neuropathologica Communications.
[15] L. Shaw,et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features , 2017, Movement disorders : official journal of the Movement Disorder Society.
[16] D. Selkoe,et al. A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations , 2017, Movement disorders : official journal of the Movement Disorder Society.
[17] C. Adler,et al. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. , 2017, Biomarkers in medicine.
[18] J. Volkmann,et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease , 2017, Acta Neuropathologica.
[19] B. Mollenhauer,et al. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &agr;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid , 2017, JAMA neurology.
[20] C. Adler,et al. Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. , 2016, Journal of Parkinson's disease.
[21] M. Esiri,et al. Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.
[22] R. Freeman,et al. The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease , 2016, Neurology.
[23] W. Kang,et al. Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients , 2016, Scientific Reports.
[24] E. Tolosa,et al. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study , 2016, The Lancet Neurology.
[25] Arthur W. Toga,et al. CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study , 2016, Acta Neuropathologica.
[26] C. Adler,et al. Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings , 2016, Movement disorders : official journal of the Movement Disorder Society.
[27] Seung‐Mo Hong,et al. Alpha‐synuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker , 2016, Movement disorders : official journal of the Movement Disorder Society.
[28] P. Cortelli,et al. Skin nerve misfolded α‐synuclein in pure autonomic failure and Parkinson disease , 2016, Annals of neurology.
[29] L. Parkkinen,et al. Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease , 2015, Neurology.
[30] L. Hazrati,et al. Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease , 2015, Neurology.
[31] Agostino Baruzzi,et al. Skin nerve &agr;-synuclein deposits: A biomarker for idiopathic Parkinson disease , 2014, Neurology.
[32] H. Shill,et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease , 2014, Neurology.
[33] Brit Mollenhauer,et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.
[34] P. Damier,et al. Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms , 2010, PloS one.
[35] H. Shill,et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders , 2010, Acta Neuropathologica.
[36] Aneeka M Hancock,et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.
[37] V. Calabrese,et al. PROJECTED NUMBER OF PEOPLE WITH PARKINSON DISEASE IN THE MOST POPULOUS NATIONS, 2005 THROUGH 2030 , 2007, Neurology.
[38] A. Kakita,et al. Degeneration of Cardiac Sympathetic Nerve Begins in the Early Disease Process of Parkinson’s Disease , 2007, Brain pathology.
[39] N. Perkins,et al. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. , 2006, American journal of epidemiology.
[40] H. Braak,et al. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.
[41] J. Cummings,et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.
[42] Johan Marinus,et al. Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.
[43] R. Doty,et al. Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory function , 1984, Physiology & Behavior.
[44] Han-Joon Kim,et al. Submandibular gland is a suitable site for alpha synuclein pathology in Parkinson disease. , 2019, Parkinsonism & related disorders.
[45] L. Chahine,et al. Revision of Diagnosis in Early Parkinsonism with Abnormal Dopamine Transporter Imaging. , 2019, Journal of Parkinson's disease.
[46] C. Adler,et al. The Search for a Peripheral Biopsy Indicator of &agr;-Synuclein Pathology for Parkinson Disease , 2017, Journal of neuropathology and experimental neurology.
[47] J. Volkmann,et al. Skin biopsies in the differential diagnosis of parkinsonism: are we ready for simplified protocols? , 2016, Brain : a journal of neurology.
[48] T. Foltynie,et al. The ongoing pursuit of neuroprotective therapies in Parkinson disease , 2015, Nature Reviews Neurology.
[49] J. Woulfe,et al. Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease. , 2015, Neurology.
[50] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.